This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Male and Female Volunteers

This study has been terminated.
(The trial is terminated due to re-evaluation of the compound)
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk A/S
ClinicalTrials.gov Identifier:
NCT00665665
First received: April 23, 2008
Last updated: December 22, 2016
Last verified: December 2016
  Purpose
This trial will be conducted in the United States of America (USA). The aim of the trial is to investigate whether the drug is safe, well tolerated and to investigate the efficacy of NNC 0070-0002-0182 for the treatment of obesity. The subjects will be treated with drug and placebo. This registration covers the phase 2 part of a combined phase 1/phase 2 trial (phase 1 part of trial conducted between November 2007 and April 2008).

Condition Intervention Phase
Metabolism and Nutrition Disorder Obesity Drug: NNC 0070-0002-0182 Drug: placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Healthy Male and Female Volunteers

Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:
  • To determine the safety and tolerability of NNC 0070-0002-0182 multiple doses [ Time Frame: after 6 weeks ]

Secondary Outcome Measures:
  • Pharmacokinetics of NNC 0070-0002-0182 and its isomer [ Time Frame: at 8 weeks ]
  • Assessment of changes in food consumption and hunger [ Time Frame: at 6 weeks ]
  • Change in weight, waist and hip measurements and mood [ Time Frame: at 6 weeks ]
  • Change in body composition and resting metabolism [ Time Frame: at 6 weeks ]
  • Intervention arm D only: Change in insulin sensitivity (HOMA) [ Time Frame: at 6 weeks ]
  • Intervention arm D only: Change from baseline in body fat (DEXA) [ Time Frame: at 6 weeks ]
  • Intervention arm D only: Change from baseline in indirect calorimetry [ Time Frame: at 6 weeks ]
  • Intervention arm D only: Change from baseline in adiponectin, hsCRP [ Time Frame: at 6 weeks ]
  • Intervention arm D only: Antibody assessment [ Time Frame: at 10 weeks ]

Enrollment: 101
Study Start Date: November 2007
Study Completion Date: October 2008
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A Drug: NNC 0070-0002-0182
4mg initial dose (12 subjects active; 3 subjects placebo); 2mg weekly maintenance dose; for s.c. injection 20mg/vial
Drug: placebo
Placebo for s.c. injection
Experimental: B Drug: placebo
Placebo for s.c. injection
Drug: NNC 0070-0002-0182
12mg initial dose (12 subjects active; 3 subjects placebo); 6mg weekly maintenance dose; for s.c. injection 20mg/vial
Experimental: C Drug: placebo
Placebo for s.c. injection
Drug: NNC 0070-0002-0182
32mg initial dose (12 subjects active; 3 subjects placebo); 16mg weekly maintenance dose; for s.c. injection 20mg/vial
Experimental: D Drug: placebo
Placebo for s.c. injection
Drug: NNC 0070-0002-0182
60mg initial dose (12 subjects active; 3 subjects placebo); 30mg weekly maintenance dose; for s.c. injection 20mg/vial

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Body mass index (BMI) between 30.0-39.0 kg/m2 (obese)
  • Females who consent to using double barrier method of contraception, are post-menopausal and older than 50 years, or have had total hysterectomy

Exclusion Criteria:

  • Clinically significant diseases
  • Blood pressure greater than 140/90 mmHg
  • Evidence of depression
  • Recent diet attempts, treatment with diet drugs (within 3 months)
  • Liposuction or other surgery for weight loss within the last year
  • Evidence of eating disorders (bulimia, binge eating)
  • Restricted diets (Kosher, vegetarian)
  • Smoker or history of drug or alcohol abuse
  • Females of childbearing potential: positive pregnancy test
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00665665

Locations
United States, Indiana
Novo Nordisk Investigational Site
Evansville, Indiana, United States, 47710
United States, Wisconsin
Novo Nordisk Investigational Site
Madison, Wisconsin, United States, 53704
Sponsors and Collaborators
Novo Nordisk A/S
Investigators
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
  More Information

Additional Information:
Responsible Party: Novo Nordisk A/S
ClinicalTrials.gov Identifier: NCT00665665     History of Changes
Other Study ID Numbers: NN9112-1846
Study First Received: April 23, 2008
Last Updated: December 22, 2016

Additional relevant MeSH terms:
Overweight
Nutrition Disorders
Body Weight
Signs and Symptoms

ClinicalTrials.gov processed this record on June 27, 2017